How To Clean Out With Ibs C

What is TRULANCE and how is information technology used?

TRULANCE is a prescription medicine used in adults to care for:

• a type of constipation called chronic idiopathic constipation (CIC). Idiopathic means the cause of the constipation is unknown.
• irritable bowel syndrome with constipation (IBS-C).

It is non known if TRULANCE is safe and effective in children less than xviii years of age.

What are the possible side effects of TRULANCE?

TRULANCE can cause serious side effects, including:

• Run into "What is the most important information I should know about TRULANCE?"
• Diarrhea is the most mutual side effect of TRULANCE, and it can sometimes be astringent.
  • Diarrhea ofttimes begins within the commencement 4 weeks of TRULANCE treatment.

Stop taking TRULANCE and call your doctor if you develop severe diarrhea.

These are not all the possible side effects of TRULANCE. Call your dr. for medical communication nigh side effects. Y'all may written report side furnishings to FDA at ane-800-FDA-1088.

Alert

Hazard OF SERIOUS Dehydration IN PEDIATRIC PATIENTS

• TRULANCE is contraindicated in patients less than 6 years of historic period; in nonclinical studies in young juvenile mice assistants of a single oral dose of plecanatide caused deaths due to dehydration [see CONTRAINDICATIONS, Utilise In Specific Populations].
• Avoid employ of TRULANCE in patients vi years to less than xviii years of age [see WARNINGS AND PRECAUTIONS, Utilise In Specific Populations].
• The safety and effectiveness of TRULANCE take not been established in patients less than eighteen years of age [see Use In Specific Populations].

DESCRIPTION

TRULANCE (plecanatide) is a guanylate cyclase-C (GC-C) agonist. Plecanatide is a sixteen amino acid peptide with the post-obit chemic proper name: L-Leucine, Fifty-asparaginyl-L-α-aspartyl-Fifty-α-glutamyl-50-cysteinyl-50-αglutamyl-Fifty-leucyl-Fifty-cysteinyl-Fifty-valyl-L-asparaginyl-Fifty-valyl-Fifty-alanyl-L-cysteinyl-L-threonylglycyl-Lcysteinyl-, cyclic (4→12),(7→15)-bis(disulfide).

The molecular formula of plecanatide is C₆₅H₁₀₄North_xviiiO₂₆S₄ and the molecular weight is 1682 Daltons. The amino acid sequence for plecanatide is shown below:

The solid lines linking cysteines illustrate disulfide bridges.

Plecanatide is an amorphous, white to off-white powder. Information technology is soluble in h2o. TRULANCE tablets are supplied as 3 mg tablets for oral administration. The inactive ingredients are magnesium stearate and microcrystalline cellulose.

3 pharmacies near 11430 accept coupons for Trulance (Brand Names:Trulance for 3MG)

Rite Assist Chemist's

$624.99

Est. Regular Price

View Coupon

INDICATIONS

TRULANCE is indicated in adults for the handling of:

• chronic idiopathic constipation (CIC).
• irritable bowel syndrome with constipation (IBS-C).

DOSAGE AND Administration

Recommended Dosage

The recommended dosage of TRULANCE for the treatment of CIC and IBS-C is 3 mg taken orally in one case daily.

Grooming And Administration Instructions

• Take TRULANCE with or without food [come across CLINICAL PHARMACOLOGY].
• If a dose is missed, skip the missed dose and have the next dose at the regular time. Do not accept ii doses at the same time.
• Consume a tablet whole for each dose.
• For developed patients with swallowing difficulties, TRULANCE tablets tin can be crushed and administered orally either in applesauce or with water or administered with water via a nasogastric or gastric feeding tube. Mixing TRULANCE crushed tablets in other soft foods or in other liquids has not been tested.

Oral Administration In Applesauce

1. In a clean container, crush the TRULANCE tablet to a powder and mix with 1 teaspoonful of room temperature applesauce.
2. Consume the entire tablet-applesauce mixture immediately. Practise not shop the mixture for subsequently use.

Oral Administration In Water

1. Place the TRULANCE tablet in a make clean cup.
2. Cascade approximately 30 mL of room temperature water into the cup.
3. Mix by gently swirling the tablet and water mixture for at least 10 seconds. The TRULANCE tablet volition fall apart in the water.
4. Swallow the unabridged contents of the tablet-water mixture immediately.
5. If whatever portion of the tablet is left in the cup, add another thirty mL of water to the cup, swirl for at least x seconds, and swallow immediately.
6. Do not store the tablet-h2o mixture for later employ.

Administration With Water Via A Nasogastric Or Gastric Feeding Tube

1. Place the TRULANCE tablet in a make clean cup with thirty mL of room temperature h2o.
2. Mix by gently swirling the tablet and water mixture for at least 15 seconds. The TRULANCE tablet volition autumn apart in the water.
3. Flush the nasogastric or gastric feeding tube with 30 mL of water using a catheter tip syringe.
4. Draw up the mixture using the syringe and immediately administer via the nasogastric or gastric feeding tube. Do not reserve for future utilise.
5. If any portion of the tablet is left in the loving cup, add another 30 mL of h2o to the loving cup, swirl for at least 15 seconds, and using the aforementioned syringe, administer via the nasogastric or gastric feeding tube.
6. Using the same or a fresh syringe, flush the nasogastric or gastric feeding tube with at to the lowest degree 10 mL of h2o.

HOW SUPPLIED

Dosage Forms And Strengths

TRULANCE Tablets:

3 mg: white to off-white, manifestly, round tablet debossed with "SP" on one side and "iii" for 3 mg on the other side.

Storage And Handling

TRULANCE tablets are packaged in an aluminum foil unit dose blister pack of 30 in a child-resistant pack or in a white, opaque, loftier-density polyethylene circular bottle with a screw-top polypropylene child-resistant cap and heat-activated induction seal. Each canteen container-closure system too contains a desiccant and a polyester coil.

TRULANCE 3 mg tablets are white to off-white, plain and circular, debossed with "SP" on 1 side and "3" for iii mg on the other side and supplied as:

NDC Number	Size
65649-003-xxx	Canteen of xxx
70194-003-30	Aluminum foil unit dose blister pack of 30 in a child-resistant pack

Store at room temperature, 20 to 25°C (68 to 77°F); excursions permitted to 15 to 30°C (59 to 86°F) [encounter USP Controlled Room Temperature].

Go on TRULANCE in a dry identify. Protect from wet. For bottles, keep TRULANCE in the original bottle. Do non remove desiccant from the bottle. Do not subdivide or repackage.

Distributed by: Salix Pharmaceuticals, a division of Bausch Wellness US, LLC, Bridgewater, NJ 08807 Usa. Revised: Apr 2022

SLIDESHOW

How to Go Rid of Hemorrhoids: Types, Causes and Treatments See Slideshow

Side Effects & Drug Interactions

SIDE EFFECTS

Clinical Trials Feel

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in exercise.

Demographic characteristics were comparable between the TRULANCE and placebo groups in all studies [run across Clinical Studies].

Chronic Idiopathic Constipation (CIC)

The safety data described below reflect data from 1,733 adult patients with CIC randomized in ii double-bullheaded, placebo-controlled clinical trials (Written report 1 and Study two) to receive placebo or 3 mg of TRULANCE in one case daily for 12 weeks.

Nigh Common Agin Reactions

Tabular array 1 provides the incidence of adverse reactions reported in at to the lowest degree ii% of CIC patients in the TRULANCE-treated group and at an incidence that was greater than in the placebo grouping.

Table 1: Most Mutual Adverse Reactions^a in Two Placebo-Controlled Trials of TRULANCE [Study 1 and Written report 2] in Patients with CIC

Agin Reaction	TRULANCE, iii mg (North = 863) %	Placebo (N = 870) %
Diarrheab	5	ane
a: Reported in at least 2% of TRULANCE-treated patients with CIC and at an incidence greater than placebo. b: Verbatim reports of diarrhea were recorded equally agin reactions; reports of loose stools and increment in stool frequency were recorded every bit adverse reactions if they were besides reported to exist bothersome to the patient.

Diarrhea

The majority of reported cases of diarrhea occurred within four weeks of treatment initiation. Severe diarrhea was reported in 0.6% of TRULANCE-treated patients compared to 0.3% of placebo-treated patients. Severe diarrhea was reported to occur within the beginning 3 days of handling [see WARNINGS AND PRECAUTIONS].

Adverse Reactions Leading to Discontinuation

Discontinuations due to adverse reactions occurred in four% of TRULANCE-treated patients and 2% of placebo-treated patients. The most mutual adverse reaction leading to discontinuation was diarrhea: ii% of TRULANCE-treated patients and 0.v% of placebo-treated patients withdrew due to diarrhea.

Less Common Adverse Reactions

Agin reactions reported in less than ii% of TRULANCE-treated patients and at an incidence greater than placebo were: sinusitis, upper respiratory tract infection, abdominal amplification, flatulence, abdominal tenderness, and increased liver biochemical tests (2 patients with alanine aminotransferase (ALT) greater than 5 to 15 times the upper limit of normal and 3 patients with aspartate aminotransferase (AST) greater than 5 times the upper limit of normal).

Irritable Bowel Syndrome With Constipation (IBS-C)

The safety data described below reflect data from 1,449 adults patients with IBS-C randomized in two double-blind, placebo-controlled clinical trials (Report 3 and Report iv) to receive placebo or 3 mg TRULANCE once daily for 12 weeks.

About Common Adverse Reactions

Table 2 provides the incidence of adverse reactions reported in at least 2% of IBS-C patients treated with TRULANCE and at an incidence that was greater than in the placebo group.

Tabular array 2: Virtually Mutual Adverse Reactions^a in Two Placebo-Controlled Trials of TRULANCE [Study iii and Study iv] in Patients with IBS-C

Adverse Reaction	TRULANCE, 3 mg (N = 723) %	Placebo (North = 726) %
Diarrheab	4.3	1
a: Reported in at least 2% of TRULANCE-treated patients with IBS-C and at an incidence greater than placebo. b: Verbatim reports of diarrhea were recorded as adverse reactions; reports of loose stools and increment in stool frequency were recorded as agin reactions if they were likewise reported to exist bothersome to the patient.

Diarrhea

The majority of reported cases of diarrhea occurred within four weeks of treatment initiation. Severe diarrhea was reported in ane% of TRULANCE-treated patients compared to 0.one% of placebo-treated patients [encounter WARNINGS AND PRECAUTIONS]. Severe diarrhea was reported to occur within the starting time 24-hour interval of handling.

Adverse Reactions Leading to Discontinuation

Discontinuations due to adverse reactions occurred in 2.five% of TRULANCE-treated patients and 0.4% of placebo-treated patients. The most common agin reaction leading to discontinuation was diarrhea: ane.two% of TRULANCE-treated patients and 0% of placebo-treated patients withdrew due to diarrhea.

Less Common Agin Reactions

Adverse reactions reported in 1% or more but less than 2% of TRULANCE-treated patients and at an incidence greater than placebo were: nausea, nasopharyngitis, upper respiratory tract infection, urinary tract infection, and dizziness. Two patients reported increased liver biochemical tests (alanine aminotransferase (ALT) greater than 5 to fifteen times the upper limit of normal).

Postmarketing Experience

The following agin reactions accept been identified during mail-approving utilise of TRULANCE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or plant a causal relationship to TRULANCE exposure.

Hypersensitivity Reactions: peel itching, hives, rash

Vomiting

DRUG INTERACTIONS

No Information Provided

WARNINGS

Included equally part of the "PRECAUTIONS" Section

PRECAUTIONS

Take chances Of Serious Dehydration In Pediatric Patients

TRULANCE is contraindicated in patients less than 6 years of age. The safety and effectiveness of TRULANCE in patients less than 18 years of age have non been established. In young juvenile mice (man age equivalent of approximately 1 month to less than 2 years), plecanatide increased fluid-secretion into the intestines as a issue of stimulation of guanylate cyclase-C (GC-C), resulting in mortality in some mice within the first 24 hours, apparently due to dehydration. Due to increased intestinal expression of GC-C, patients less than half dozen years of age may be more than probable than patients six years of age and older to develop severe diarrhea and its potentially serious consequences.

Avoid the use of TRULANCE in patients vi years to less than xviii years of age. Although there were no deaths in older juvenile mice, given the deaths in younger mice and the lack of clinical safety and efficacy information in pediatric patients, avoid the use of TRULANCE in patients 6 years to less than eighteen years of age [encounter CONTRAINDICATIONS, Diarrhea, Use In Specific Populations].

Diarrhea

Diarrhea was the near common adverse reaction in 4 placebo-controlled clinical trials, two in patients with CIC and ii in patients with IBS-C. Severe diarrhea was reported in 0.6% of patients in two trials in patients with CIC and in 0.6% of patients in the two trials in patients with IBS-C [see Adverse REACTIONS]. If severe diarrhea occurs, suspend dosing and rehydrate the patient.

Patient Counseling Data

Propose the patient to read the FDA-approved patient labeling (PATIENT INFORMATION).

Propose Patients:

Diarrhea

To stop TRULANCE and contact their healthcare provider if they experience severe diarrhea [encounter WARNINGS AND PRECAUTIONS].

Adventitious Ingestion

Accidental ingestion of TRULANCE in children, particularly in children less than 6 years of age, may result in severe diarrhea and aridity. Instruct patients to have steps to store TRULANCE securely and out of reach of children and to dispose of unused TRULANCE [see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS].

Administration And Treatment Instructions

• To take TRULANCE in one case daily with or without nutrient [encounter DOSAGE AND ADMINISTRATION].
• If a dose is missed, skip the missed dose and have the adjacent dose at the regular fourth dimension. Do not take two doses at the aforementioned time.
• To swallow TRULANCE tablets whole.
• If adult patients take swallowing difficulties, TRULANCE tablets can exist crushed and administered orally in either applesauce or with water, or administered with water via a nasogastric or gastric feeding tube, as described in the Medication Guide.
• To go on TRULANCE in a dry out place. Protect from wet. For bottles, go on TRULANCE in the original bottle. Do not remove desiccant from the bottle. Do not subdivide or repackage. Remove and discard polyester coil after opening. Keep bottles closed tightly [run into HOW SUPPLIED].

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Damage Of Fertility

Carcinogenesis

The carcinogenic potential of plecanatide was assessed in 2-year carcinogenicity studies in mice and rats. Plecanatide was not tumorigenic in mice at oral doses upwards to ninety mg/kg/twenty-four hour period or in rats at oral doses upwardly to 100 mg/kg/twenty-four hour period. Limited systemic exposure to plecanatide was achieved at the tested dose levels in animals, whereas no detectable exposure occurred in humans. Therefore, animate being and homo doses should not be compared direct for evaluating relative exposure.

Mutagenesis

Plecanatide was not genotoxic in the in vitro bacterial reverse mutation (Ames) analysis, in vitro mouse lymphoma mutation assay, or the in vivo mouse os marrow micronucleus assay.

Harm Of Fertility

Plecanatide had no effect on fertility or reproductive part in male or female person mice at oral doses of upward to 600 mg/kg/day.

Use In Specific Populations

Pregnancy

Risk Summary

Plecanatide and its active metabolite are negligibly absorbed systemically post-obit oral administration [see CLINICAL PHARMACOLOGY] and maternal use is non expected to outcome in fetal exposure to the drug. The bachelor information on TRULANCE utilize in pregnant women are not sufficient to inform any drug-associated risks for major birth defects and miscarriage. In beast developmental studies, no effects on embryo-fetal development were observed with oral administration of plecanatide in mice and rabbits during organogenesis at doses much higher than the recommended human dosage.

The estimated groundwork take chances of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a groundwork take a chance of nativity defect, loss, or other adverse outcomes. In the United States full general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to iv% and 15% to twenty%, respectively.

Data

Animal data

Pregnant mice and rabbits were administered plecanatide during the period of organogenesis. At that place was no evidence of harm to embryo-fetal development at oral doses upwardly to 800 mg/kg/twenty-four hours in mice and 250 mg/kg/day in rabbits. Oral administration of up to 600 mg/kg/twenty-four hour period in mice during organogenesis through lactation produced no developmental abnormalities or effects on growth, learning and retentiveness, or fertility in the offspring through maturation.

The maximum recommended human dose is approximately 0.05 mg/kg/day, based on a sixty-kg body weight. Express systemic exposure to plecanatide was achieved in animals during organogenesis (area under the plasma concentration-time bend (AUCt) = 449 ng•h/mL in rabbits given 250 mg/kg/day). Plecanatide and its active metabolite are not measurable in human plasma following administration of the recommended clinical dosage. Therefore, creature and man doses should not be compared directly for evaluating relative exposure.

Lactation

Chance Summary

After administration of multiple doses of TRULANCE 3 mg once daily for 2 weeks to nursing mothers, plecanatide and its active metabolite were not measurable in breast milk collected at 2 hours, six hours, and 12 hours mail service-dosing. In adults, concentrations of plecanatide and its active metabolite were by and large unmeasurable in plasma following multiple doses of TRULANCE three mg once daily for up to 12 weeks [meet CLINICAL PHARMACOLOGY].

Maternal use of TRULANCE is non expected to upshot in clinically relevant exposure to plecanatide or its agile metabolite in breastfed infants. The developmental and wellness benefits of breastfeeding should be considered along with the mother's clinical need for TRULANCE and any potential agin effects on the breastfed baby from TRULANCE or from the underlying maternal condition.

Pediatric Use

TRULANCE is contraindicated in pediatric patients less than half-dozen years of age. Avoid utilize of TRULANCE in patients 6 years to less than xviii years of age [see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS]. The safety and effectiveness of TRULANCE in patients less than 18 years of age have non been established.

In nonclinical studies, deaths occurred within 24 hours in young juvenile mice (human being age equivalent of approximately ane month to less than 2 years) post-obit oral administration of plecanatide, as described beneath in Juvenile Fauna Toxicity Data. Considering of increased abdominal expression of GC-C, patients less than half dozen years of age may be more probable than patients half dozen years of age and older to develop diarrhea and its potentially serious consequences. TRULANCE is contraindicated in patients less than half-dozen years of historic period. Given the deaths in immature juvenile mice and the lack of clinical rubber and efficacy data in pediatric patients, avert the use of TRULANCE in patients half-dozen years to less than 18 years of age.

Juvenile Brute Toxicity Data

Unmarried oral doses of plecanatide at 0.5 mg/kg and ten mg/kg acquired mortality in young juvenile mice on postnatal days 7 and 14, respectively (man age equivalent of approximately 1 calendar month to less than 2 years). Treatment-related increases in the weight of intestinal contents were observed in juvenile mice post-obit single doses of plecanatide on postnatal day 14 (man age equivalent of approximately less than two years), consequent with increased fluid in the intestinal lumen. Although the recommended human dose is approximately 0.05 mg/kg/twenty-four hours, based on a 60-kg body weight, plecanatide and its active metabolite are not measurable in adult human being plasma, whereas systemic absorption was demonstrated in the juvenile animal toxicity studies. Animal and human doses should not be compared direct for evaluating relative exposure.

Geriatric Employ

Chronic Idiopathic Constipation (CIC)

Of 2,601 subjects in placebo-controlled clinical trials of TRULANCE, 273 (10%) were 65 years of age and over, and 47 (ii%) were 75 years and over. Clinical studies of TRULANCE did non include sufficient numbers of patients anile 65 and over to determine whether they respond differently from patients 18 years to less than 65 years of age.

Irritable Bowel Syndrome With Constipation (IBS-C)

Of 1,621 subjects in the placebo-controlled clinical studies of TRULANCE, 134 (8.iii%) were 65 years of age and over, and 25 (i.5%) were 75 years and over. Clinical studies of TRULANCE did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from patients 18 years to less than 65 years of historic period.

Overdosage & Contraindications

OVERDOSE

No Information Provided

CONTRAINDICATIONS

TRULANCE is contraindicated in:

• Patients less than six years of age due to the gamble of serious aridity [see WARNINGS AND PRECAUTIONS, Use In Specific Populations].
• Patients with known or suspected mechanical gastrointestinal obstruction.

CLINICAL PHARMACOLOGY

Mechanism Of Action

Plecanatide is a structural analog of human uroguanylin, and similarly to uroguanylin, plecanatide functions every bit a guanylate cyclase-C (GC-C) agonist. Both plecanatide and its active metabolite demark to GC-C and human action locally on the luminal surface of the intestinal epithelium. Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP). Elevation of extracellular cGMP has been associated with a decrease in the activity of pain-sensing fretfulness in animate being models of visceral pain. Superlative of intracellular cGMP stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly through activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid and accelerated transit. In animal models, plecanatide has been shown to increment fluid secretion into the gastrointestinal (GI) tract, accelerate intestinal transit, and crusade changes in stool consistency.

In an animal model of visceral pain, plecanatide reduced intestinal muscle contractions, a measure of intestinal pain.

Pharmacodynamics

Food Effect

Subjects who received either a low-fat, low calorie (LF-LC) meal or a high fat, high calorie (HF-HC) meal reported looser stools than fasted subjects upward to 24 hours after a single dose of TRULANCE ix mg (3 times the recommended dose). In clinical studies, TRULANCE was administered with or without food [run into DOSAGE AND Assistants].

Pharmacokinetics

Assimilation

Plecanatide was minimally absorbed with negligible systemic availability following oral assistants. Concentrations of plecanatide and its active metabolite in plasma were below the limit of quantitation in the majority of analyzed plasma samples after an oral TRULANCE dose of three mg. Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (Cmax), and one-half-life (t_½) could not be calculated.

Food Effect

In a crossover study, 24 good for you subjects were given a single dose of TRULANCE 9 mg (iii times the recommended dose) in 3 different states: fasted; post-obit a low-fatty, low-calorie meal (LF-LC; approximately 350 calories: 17% from fat, 66% from carbohydrate, and 17% from protein); and following a high-fat, loftier-calorie meal (HF-HC; approximately 1,000 calories: 60% from fat, 25% from carbohydrate, and xv% from protein). Plecanatide was detected in one subject (fasted country) at 0.v and i hour mail service dose. Plecanatide concentrations were below the limit of quantitation for all other fourth dimension points and for all other subjects. The agile metabolite was not detected in any subject.

Distribution

Given that plecanatide concentrations post-obit clinically relevant oral doses were not measurable, plecanatide is expected to be minimally distributed in tissues. Oral plecanatide was localized to the GI tract where information technology exerted its effects as a GC-C agonist with negligible systemic exposure. Plecanatide exhibited petty to no binding to human being serum albumin or man α-one-acid glycoprotein.

Elimination

Metabolism

Plecanatide was metabolized in the GI tract to an active metabolite by loss of the terminal leucine moiety. Both plecanatide and the metabolite were proteolytically degraded inside the abdominal lumen to smaller peptides and naturally occurring amino acids.

Excretion

No excretion studies have been conducted in humans. Plecanatide and its active metabolite were not measurable in plasma following administration of the recommended clinical doses.

Drug Interaction Studies

Neither plecanatide nor its active metabolite inhibited the cytochrome P450 (CYP) enzymes 2C9 and 3A4, and they did non induce CYP3A4 in vitro.

Plecanatide and its active metabolite were neither substrates nor inhibitors of the transporters P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) in vitro.

Clinical Studies

Chronic Idiopathic Constipation (CIC)

The efficacy of TRULANCE for the direction of symptoms of CIC was established in two 12-week, double-blind, placebo-controlled, randomized, multicenter clinical studies in developed patients (Written report ane and Written report 2). In the Intention-to-Treat (ITT) population, a total of 905 patients (Written report 1) and 870 patients (Study 2) were randomized 1:ane to either placebo or TRULANCE 3 mg, once daily. In clinical studies, study medication was administered without respect to food intake. Demographics for these studies included an overall hateful historic period of 45 years (range eighteen to 80 years), eighty% female, 72% white, and 24% blackness.

To be eligible for the studies, patients were required to meet modified Rome III criteria for at least 3 months prior to the screening visit, with symptom onset for at to the lowest degree six months prior to diagnosis. Rome Three criteria were modified to require that patients report less than 3 defecations per calendar week, rarely have a loose stool without the utilise of laxatives, not utilise manual maneuvers to facilitate defecations, and not encounter criteria for IBS-C. In improver, patients were required to report at least two of the following symptoms:

• Straining during at least 25% of defections
• Lumpy or hard stool in at to the lowest degree 25% of defecations
• Sensation of incomplete evacuations for at least 25% of defecations
• Sensation of anorectal obstacle/blockage for at least 25% of defecations

Patients who met these criteria were also required to demonstrate the following during the concluding 2 weeks of the screening menstruation:

• Less than iii complete spontaneous bowel movements (CSBMs) (a CSBM is an SBM that is associated with a sense of complete evacuation) in each of the two weeks
• Bristol Stool Form Scale (BSFS) of six or 7 in less than 25% of spontaneous bowel movements (SBMs) (an SBM is a bowel motility occurring in the absence of laxative use)
• One out of the following three:
  • BSFS of one or two in at least 25% of defecations
  • A straining value recorded on at to the lowest degree 25% of days when a BM was reported
  • At least 25% of BMs result in a sense of incomplete evacuation

The efficacy of TRULANCE was assessed using a responder analysis and change-from-baseline in CSBM and SBM endpoints. Efficacy was assessed using data provided by patients on a daily basis in an electronic diary.

A responder was defined as a patient who had at to the lowest degree 3 CSBMs in a given week and an increase of at least 1 CSBM from baseline in the aforementioned week for at least 9 weeks out of the 12-week treatment period and at least iii of the concluding four weeks of the written report. The responder rates are shown in Table iii.

Table 3: Efficacy Responder Rates in the Two Placebo-controlled Studies of CIC: at least 9 of 12 weeks and at least three of the terminal 4 weeks (ITT Population)

Study 1
	TRULANCE 3 mg N = 453	Placebo N = 452	Treatment Deviationa [95% CIb]
Responderc	21%	ten%	eleven% [vi.ane%, 15.4%]
Study two
	TRULANCE 3 mg N = 430	Placebo N = 440	Treatment Differencea [95% CIb]
Responderc	21%	13%	8% [2.6%, 12.4%]
a: p-value <0.005 b: CI = confidence interval c: Primary endpoint defined as a patient who had a to the lowest degree three CSBMs in a given week and an increase of at least ane CSBM from baseline in the aforementioned week for at least ix weeks out of the 12-week handling period and at to the lowest degree 3 of the concluding 4 weeks of the study.

In both studies, improvements in the frequency of CSBMs/week were seen as early every bit calendar week i with improvement maintained through week 12. The difference between the TRULANCE grouping and the placebo group in the hateful change of CSBMs/week frequency from baseline to week 12 was approximately i.1 CSBMs/calendar week.

Over the 12-calendar week treatment period, improvements were observed in stool frequency (number of CSBMs/calendar week and SBMs/week) and/or stool consistency (as measured past the BSFS), and/or in the amount of straining with bowel movements (amount of time pushing or physical endeavour to pass stool) in the TRULANCE grouping as compared to placebo.

Post-obit completion of the written report drug treatment period, patients connected to record information in the daily diary for a ii-week Postal service-Handling Menstruum. During this time, TRULANCE-treated patients generally returned to baseline for these study endpoints.

In Studies 1 and 2, a tertiary randomized handling arm of TRULANCE 6 mg once daily did not demonstrate boosted treatment benefit and had a greater incidence of agin reactions than TRULANCE 3 mg once daily. Therefore, TRULANCE 6 mg once daily is non recommended [see DOSAGE AND Assistants].

Irritable Bowel Syndrome With Constipation (IBS-C)

The efficacy of TRULANCE for the management of symptoms of IBS-C was established in two 12-week, double-blind, placebo-controlled, randomized, multicenter clinical studies in developed patients (Report iii and Study four). In the Intention-to- Care for (ITT) population, a full of 699 patients (Study 3) and 754 patients (Report 4) received treatment with placebo or TRULANCE three mg in one case daily. In clinical studies, study medication was administered without respect to food intake. Demographics for these studies included an overall mean age of 44 years (range 18 to 83 years), 74% female, 73% white, and 22% black.

To be eligible, patients were required to meet the Rome Iii criteria for IBS for at to the lowest degree 3 months prior to the screening visit, with symptom onset for at least 6 months prior to diagnosis. Diagnosis required recurrent abdominal hurting or discomfort at to the lowest degree three days/month in the last 3 months associated with two or more than of 1) improvement with defecation, 2) onset associated with a modify in frequency of stool, and 3) onset associated with a change in form (appearance) of stool. Patients likewise met the IBS-C differentiation criteria for constipation, characterized by a stool pattern such that at least 25% of defecations are hard or lumpy stools and no more than 25% of defecations are loose or watery stool.

Patients who met these criteria were excluded if they demonstrated the post-obit during the last 2 weeks of the screening menstruum:

• Worst abdominal pain intensity (WAPI) score of 0 on an 11-point calibration for more than 2 days during each calendar week
• An average WAPI of less than iii for either week
• More than than three complete spontaneous bowel movements (CSBMs) or more than than six spontaneous bowel movements (SBMs) per calendar week in either week
• Bristol Stool Form Scale (BSFS) of vii for whatever SBM recorded
• More than 1 twenty-four hours in either week with a BSFS of vi for any SBM recorded
• No use of rescue laxative (bisacodyl) inside 72 hours earlier randomization

The efficacy of TRULANCE was assessed using a responder analysis based on abdominal pain intensity and a stool frequency responder (CSBM) endpoint. Efficacy was assessed using information provided by patients on a daily basis through an electronic phone diary system.

A responder was defined as a patient who met both the abdominal hurting intensity and stool frequency responder criteria in the aforementioned week for at to the lowest degree 6 of the 12 treatment weeks. The intestinal pain intensity and stool frequency responder criteria assessed each week were defined equally:

• Abdominal hurting intensity responder: a patient who experienced a decrease in the weekly average of worst abdominal pain in the by 24 hours score (measured daily) of at least 30% compared with baseline weekly average.
• Stool frequency responder: a patient who experienced an increase of at to the lowest degree i CSBM per calendar week from baseline.

The responder rates are shown in Table 4.

Table four: Efficacy Responder Rates in the Ii Placebo-controlled Studies of IBS-C:Overall Responder for at least six of the 12 Treatment Weeks (ITT Population)

Study iii
	Placebo North = 350	TRULANCE iii mg N = 349	Handling Difference [95% CIa]
Responderb	eighteen%	30%	12% [6%, 18%]
Components of Responder Endpoint
Abdominal Pain Responderc	32%	41%
CSBM Responderd	35%	48%
Study 4
	Placebo North = 379	TRULANCE iii mg N = 375	Treatment Deviation [95% CIa]
Responderb	fourteen%	21%	seven% [ii%, 13%]
Components of Responder Endpoint
Abdominal Hurting Responderc	23%	33%
CSBM Responderd	28%	34%
a: CI = confidence interval b: A responder for these trials was defined as a patient who met both the abdominal pain and CSBM weekly responder criteria for at to the lowest degree six of the 12 weeks. c: An abdominal pain responder was defined every bit a patient who met the criteria of at least xxx% reduction from baseline in weekly average of the worst daily abdominal pain, for at least 6 of the 12 weeks. d: A CSBM responder was defined as a patient who achieved an increment in at to the lowest degree 1 CSBM per week, from baseline, for at least 6 of 12 weeks.

In both studies, the proportion of responders who were also weekly responders for at least 2 of the iv treatment weeks in month iii, the terminal calendar month of treatment was greater in the TRULANCE groups compared to placebo.

Over the 12-week handling period, improvements were observed in both stool consistency (equally measured past the BSFS) and in the corporeality of straining with bowel movements (amount of time pushing or concrete attempt to pass stool) in the 3 mg TRULANCE grouping equally compared to placebo.

Following completion of the study drug treatment period, patients continued to record data in the daily diary for a 2-calendar week Postal service-Handling Period. During this fourth dimension, TRULANCE-treated patients generally returned to baseline for these study endpoints.

In Studies three and 4, a third randomized treatment arm of TRULANCE 6 mg once daily did non demonstrate additional treatment benefit over the 3 mg dose. Therefore, TRULANCE half dozen mg one time daily is non recommended [see DOSAGE AND ADMINISTRATION].

PATIENT Data

TRULANCE^®
(TROO lans)
(plecanatide) tablets, for oral use

What is the near important information I should know most TRULANCE?

• Do not give TRULANCE to children who are less than half dozen years of age. Information technology may harm them.
• You should not requite TRULANCE to children half-dozen years to less than eighteen years of historic period. It may damage them.

Come across "What are the possible side effects of TRULANCE?" for more information near side furnishings.

What is TRULANCE?

TRULANCE is a prescription medicine used in adults to treat:

• a type of constipation chosen chronic idiopathic constipation (CIC). Idiopathic ways the cause of the constipation is unknown.
• irritable bowel syndrome with constipation (IBS-C).

Information technology is not known if TRULANCE is safe and effective in children less than xviii years of age.

Who should not take TRULANCE?

• Do non requite TRULANCE to children who are less than 6 years of historic period.
• Do not take TRULANCE if a medico has told you lot that yous have a bowel blockage (intestinal obstruction).

Earlier taking TRULANCE, tell your dr. about all of your medical conditions, including if yous:

• are pregnant or program to get pregnant. Information technology is not known if TRULANCE will harm your unborn infant.
• are breastfeeding or plan to breastfeed. Talk with your doctor virtually the best way to feed your infant if you take TRULANCE.

Tell your doctor about all the medicines yous take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I take TRULANCE?

• Take TRULANCE exactly as your doc tells you to take it.
• Take TRULANCE past mouth, 1 time each day with or without food.
• If yous miss a dose, skip the missed dose. Take the next dose at your regular time. Practice not take two doses at the aforementioned fourth dimension.
• TRULANCE tablets should exist swallowed whole.

Adults who cannot swallow TRULANCE tablets whole may beat out the TRULANCE tablet and mix with absurdity or deliquesce TRULANCE in water earlier swallowing. TRULANCE tablets may also be taken with water by adults through a nasogastric or gastric feeding tube.

It is non known if TRULANCE is safe and effective when crushed and mixed with other foods or dissolved in other liquids. Taking TRULANCE in absurdity:

• Beat out the TRULANCE tablet in a clean container until information technology is a powder and mix with 1 teaspoon of room temperature absurdity.
• Swallow all of the TRULANCE and applesauce mixture right away. Practise not keep the TRULANCE and absurdity mixture for future use.

Taking TRULANCE in h2o:

• Place the TRULANCE tablet in a clean cup and pour 1 ounce (30 mL) of room temperature h2o into the loving cup.
• Gently swirl the TRULANCE tablet and water for at to the lowest degree x seconds. The TRULANCE tablet will fall apart in the h2o.
• Swallow all of the TRULANCE tablet and h2o mixture right away. Practice not keep the mixture for hereafter utilize.
• If yous see any role of the tablet left in the cup, add another 1 ounce (30 mL) of h2o to the cup, swirl for at least 10 seconds, and swallow right away.

Taking TRULANCE through a nasogastric or gastric feeding tube:

Assemble the supplies you will need to have your TRULANCE dose. Your doctor should tell you lot what size catheter tip syringe you will need for your dose. Ask your md if you have any questions nearly how to give TRULANCE the right way.

• Place the TRULANCE tablet in a clean cup with i ounce (30 mL) of room temperature water.
• Gently swirl the TRULANCE tablet and water for at least 15 seconds. The TRULANCE tablet will fall apart in the water.
• Flush the nasogastric or gastric feeding tube with 1 ounce (30 mL) of water.
• Draw up the TRULANCE tablet and h2o mixture into a catheter tip syringe and requite right away through the nasogastric or gastric feeding tube. Do not keep the mixture for future use.
• If you run into whatsoever function of the tablet left in the cup, add some other ane ounce (xxx mL) of water to the cup, swirl for at to the lowest degree xv seconds and use the aforementioned catheter tip syringe to give the mixture through the nasogastric or gastric feeding tube.
• Using the aforementioned or another catheter tip syringe, flush the nasogastric or gastric feeding tube with at least 10 mL of water.

What are the possible side effects of TRULANCE?

TRULANCE can cause serious side furnishings, including:

• Come across "What is the virtually important information I should know most TRULANCE?"
• Diarrhea is the most common side effect of TRULANCE, and it can sometimes be astringent.
  • Diarrhea often begins within the first four weeks of TRULANCE treatment.

Stop taking TRULANCE and phone call your md if you develop severe diarrhea.

These are not all the possible side furnishings of TRULANCE.

Phone call your doctor for medical communication nearly side effects. You may study side effects to FDA at 1-800-FDA-1088.

How should I shop TRULANCE?

• Store TRULANCE at room temperature between 68°F to 77°F (20°C to 25°C).
• Keep TRULANCE in a secure place and in the bottle or blister pack that it comes in.
• The TRULANCE canteen contains a desiccant packet to help keep your medicine dry (protect it from moisture). Exercise not remove the desiccant packet from the bottle.
• The TRULANCE bottle contains a polyester coil to assist protect the tablets during shipping. Remove the polyester whorl from the canteen and throw information technology away after opening the canteen.
• Keep the container of TRULANCE tightly closed and in a dry place.
• Safely throw away TRULANCE that is out of date or no longer needed.

Keep TRULANCE and all medicines out of the reach of children.

General information about the safe and effective use of TRULANCE.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TRULANCE for a condition for which it was not prescribed. Exercise not give TRULANCE to other people, even if they have the aforementioned symptoms that yous have. It may impairment them.

You tin can ask your doctor or pharmacist for data nearly TRULANCE that is written for wellness professionals.

What are the ingredients in TRULANCE?

Agile ingredient: plecanatide

Inactive ingredients: magnesium stearate and microcrystalline cellulose

This Medication Guide is approved by the U.Southward. Nutrient and Drug Administration.

From

Report Problems to the Food and Drug Administration

Y'all are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Source: https://www.rxlist.com/trulance-drug.htm

Posted by: jacksonchrocied.blogspot.com

Share this post